LINCOLN PHARMA LTD Fair Value
LINCOLN · Healthcare · Current price ₹597
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹382 | 12% ROE fading to 12% over ~3 yrs, on ₹378 book |
| Relative P/E | — | Needs ≥3 peers with P/E |
| Graham floor | ₹611 | Conservative floor: √(22.5 × EPS × book value/share) |
| Analyst target | — | No analyst coverage |
Is LINCOLN PHARMA LTD undervalued?
DocStoX estimates the fair value of LINCOLN PHARMA LTD at ₹432 per share, versus the current market price of ₹597. That puts the stock about -27.7% above our fair-value estimate, which we read as "Expensive". Our confidence in this estimate is medium.
How this fair value is calculated
This estimate blends 2 independent methods: Residual income (₹382), Graham floor (₹611). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹367 (bear) to ₹432 (base) to ₹611 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on LINCOLN PHARMA LTD
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.